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A B S T R A C T
Background: Presence of cardiovascular disease (CVD) risk factors (RFs) should prompt patients and their pro-
viders to work aggressively towards controlling those that are modifiable. The extent to which a greater CVD RF
burden is related to CVD RF control in a contemporary and diverse Hispanic/Latino population is not well-
understood.
Methods: Using multicenter community-based data from the Hispanic Community Health Study/Study of Latinos,
we assessed the self-reported prevalence of hypertension, hypercholesterolemia, diabetes, and prevalent CVD
(ischemic heart disease or stroke). We used contemporaneous guidelines to define RF control. Multivariable lo-
gistic regression for complex survey sampling was used to examine whether having more CVD RFs was associated
with CVD RF control (adjusting for age, sex, Hispanic background group, education, and health insurance).
Results: Our sample included 8521 participants with at least one CVD RF or prevalent CVD. The mean age in
HCHS/SOL target population was 49 (SE 0.3) years and 56% were women. Frequency of one, two, or three self-
reported CVD RFs was 57%, 26%, 8%, respectively, and overall 9% of participants had prevalent CVD. After
adjusting for sociodemographic factors, compared to those reporting one CVD RF, individuals with three CVD RFs
were the least likely to have blood pressure, cholesterol, and glucose optimally controlled (odds ratio [OR]: 0.56;
95% confidence interval [CI]: 0.40–0.80). However, those with prevalent CVD were more likely to have all three
risk factors controlled, (OR: 1.43; 95% CI: 1.01–2.01).
Conclusion: Hispanic/Latino adults with three major CVD RFs represent a group with poor overall CVD RF control.
Secondary CVD prevention fares better. The potential contributors to inadequate CVD RF control in this highly
vulnerable group warrants further investigation.
1. Background
Hispanics/Latinos are currently the largest minority group in the
U.S. and face a disproportionate burden of cardiovascular disease
(CVD) risk factors (RFs) [1]. Control of prevalent CVD RFs remains a
public health priority as uncontrolled CVD RFs are associated with
higher costs and adverse clinical outcomes [2–5]. Several primary
prevention clinical practice guidelines provide recommendations for
control of CVD RFs including hypercholesterolemia, hypertension, and
diabetes [6–9]. Control of these and other traditional risk factors may
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prevent up to 90% of the global burden of acute myocardial infarctions,
for example [10]. For patients with established CVD, control of these
RFs remains of critical importance in preventing subsequent events [11,
12].
Reasons for poor control of CVD RFs are linked to patient, disease,
and system factors [3,13,14]. Few studies have specifically explored
how RF control varies across the spectrum of CVD RFs in diverse
vulnerable populations and in primary prevention settings. In patients
with existing CVD, control of multiple risk factors is challenging [15]
and suboptimal even in controlled clinical trial settings [16]. As a
person transitions from presence of only a single RF to those with
multiple CVD RFs to eventual overt CVD, control of RFs may improve
due to increased health awareness or alternatively, may worsen in the
setting of increased comorbid status. Understanding the patterns and
correlates of RF control across the spectrum of CVD risk may help
identify opportunities to augment both primary and secondary pre-
vention efforts. However, the extent to which CVD RF control varies
between individuals with more or less CVD risk burden has not been
extensively studied in Hispanic/Latino populations.
Our study objective was to analyze the prevalence of RF control across
the spectrum of CVD risk burden (from a single CVD RF to prevalent
CVD) in a heterogeneous sample of Hispanic/Latino participants from the
Hispanic Community Health Study/Study of Latinos (HCHS/SOL). We
hypothesized that RF control, defined by contemporaneous primary and
secondary prevention CVD guidelines, will vary across the spectrum of
CVD risk and that this variation will be associated with sociodemo-
graphic and clinical characteristics including age, sex, Hispanic back-
ground group, and access to healthcare.
2. Methods
2.1. Study population
HCHS/SOL is a population-based cohort study of the prevalence of
multiple health conditions and their RFs among Hispanic/Latinos
residing in the United States (US). The sample design and cohort selec-
tion have been previously described [17,18]. Briefly, 16,415 participants
were recruited from randomly selected households using two-stage area
probability sampling of households near four field centers (Bronx, NY;
Chicago, IL; Miami, FL; and San Diego, CA). The participants were be-
tween 18 and 74 years of age and self-identified Hispanics/Latinos
further categorized as Cuban, Central American, Dominican, Mexican,
Puerto Rican, South American, or other Hispanic/Latino heritage. We
included all eligible men and women who participated in the HCHS/SOL
baseline examination from March 2008 to June 2011 with at least one
CVD RF or prevalent CVD. All participants provided informed consent,
and approval was received from the IRBs of all participating institutions.
2.2. Risk factors ascertainment
All questionnaires were administered by trained staff to collect in-
formation pertaining to demographic characteristics andmedical history.
Participants were asked to respond to questions such as: “Has a doctor
ever said that you have high blood pressure or hypertension?“; “Has a
doctor ever said that you have high blood cholesterol?“; “Has a doctor
ever said that you have diabetes (high sugar in blood or urine)?” to assess
awareness of their own risk factors. Participants who provided affirma-
tive responses to these questions were noted to have the specific risk
Table 1
Characteristics of the HCHS/SOL target population by cardiovascular risk factor burden.
CV Risk Factor Burden (n ¼ 8521) p-value
1 RF 2 RFs 3RFs Prevalent CVDa
N (%) 4456 (57%) 2473 (26%) 852 (8%) 740 (9%)
Age, mean (S.E.) 44 (0.3) 52 (0.4) 58 (0.6) 55 (0.9) <0.001
Female 2785 (56%) 1656 (59%) 580 (61%) 365 (40%) <0.001
Hispanic/Latino Background Group <0.001
Dominican 394 (10%) 265 (12%) 99 (12%) 73 (11%)
Central American 440 (7%) 230 (6%) 64 (5%) 58 (4%)
Cuban 676 (22%) 366 (24%) 124 (26%) 129 (27%)
Mexican 1792 (37%) 921 (32%) 295 (30%) 196 (23%)
Puerto Rican 738 (17%) 494 (19%) 219 (22%) 231 (27%)
South American 293 (5%) 138 (4%) 34 (3%) 33 (4%)
Others 115 (4%) 51 (3%) 17 (2%) 18 (4%)
Education <0.001
Less than high school 1672 (33%) 1050 (39%) 434 (49%) 352 (44%)
High school or Equivalent 1064 (27%) 563 (23%) 167 (19%) 144 (20%)
Greater than HS 1630 (40%) 810 (38%) 226 (32%) 231 (36%)
Annual Income <0.001
<$20,000 1937 (46%) 1173 (54%) 447 (57%) 430 (62%)
$20,001–40,000 1412 (32%) 703 (30%) 211 (27%) 165 (28%)
$40,001–75,00 558 (15%) 273 (11%) 93 (12%) 45 (5%)
>$75,000 194 (7%) 75 (5%) 23 (4%) 27 (5%)
Foreign-Born 3799 (80%) 2215 (89%) 753 (90%) 638 (82%) <0.001
Years Living in the US 21 (0.5) 24 (0.6) 28 (0.9) 30 (1.0) <0.001
Spanish Language Preference 3669 (76%) 2127 (84%) 716 (84%) 597 (80%) <0.001
Immigrant Generation <0.001
1st 3717 (78%) 2178 (86%) 740 (88%) 623 (80%)
2nd 732 (21%) 284 (13%) 111 (12%) 114 (20%)
Health Insurance (yes) 2263 (52%) 1497 (64%) 602 (72%) 543 (78%) <0.001
Doctor Visits in Past Year, mean (SE) 2.6 (0.03) 3.1 (0.04) 3.4 (0.06) 3.3 (0.10) <0.001
Field center Bronx 1093 (29%) 701 (32%) 283 (32%) 257 (38%) 0.001
Chicago 1105 (14%) 604 (14%) 202 (14%) 175 (13%)
Miami 1106 (30%) 566 (31%) 170 (31%) 184 (33%)
San Diego 1152 (27%) 602 (24%) 197 (23%) 124 (16%)
Cardiovascular risk factors included diabetes, hypertension, and hypercholesterolemia.
N’s presented are unweighted counts of total participants in the HCHS/SOL; percentages are weighted row percentages.
a Includes participants who self-identified as having coronary heart disease or stroke.
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factors they indicated. For our primary analyses, CVD RFs were self-
reported hypertension, hyperlipidemia and diabetes. Prevalent CVD
was defined as self-report of a heart attack, coronary artery bypass sur-
gery, stent placement in coronary arteries, balloon angioplasty, or cere-
brovascular disease. In HCHS/SOL, self-reported CVD was assessed with
the following questions: “Has a doctor ever said that you had a heart
attack?“; “Have you had a balloon angioplasty, a stent, or bypass surgery
to the arteries in your heart to improve the blood flow to your heart?“;
and “Has a doctor ever said that you had a stroke?”
2.3. Risk factor control
Trained and certified clinic staff obtained blood samples and blood
pressure measurements from all HCHS-SOL participants during the
baseline visit. After a 5-min rest, blood pressure was measured three
times at 1-min intervals using an automated oscillometric device with the
participant in a seated position with the back and arm supported. The
average of the second and third blood pressure measurements was used
for this analysis. Blood lipids and lipoproteins were measured from
samples obtained after an overnight fast. Total cholesterol was measured
using a cholesterol oxidase enzymatic method and high-density lipo-
protein cholesterol with a direct magnesium/dextran sulfate method.
Triglyceride levels were measured in EDTA plasma with the use of TG GB
reagent (Roche Diagnostics) on a centrifugal analyzer. Low-density li-
poprotein cholesterol (LDL-C) was calculated using the Friedewald
equation. Plasma glucose were also measured using samples collected
after an overnight fast. Measurements of glycosylated hemoglobin (A1c)
were captured using a Tosoh G7 automated high-performance liquid
chromatography analyzer (Tosoh Bioscience Inc., San Francisco, CA).
Risk factor control was defined by guidelines contemporaneous with
HCHS/SOL Visit 1 [8,9,11,19]. Blood pressure control was defined as a
blood pressure of <140/90 mm Hg or <130/80 mm Hg if diabetes or
prevalent CVD was self-reported. Cholesterol control was defined as LDL
<130 mg/dL and/or total cholesterol <240 mg/dL [20]. For patients
with prevalent CVD or diabetes, cholesterol control was defined as
LDL<100 mg/dL. If diabetes was not reported, a fasting glucose under
100 mg/dL or A1c< 6.5% was defined as glucose control. If a participant
had prevalent diabetes, glycemic control was defined as an A1c <7%, as
has been done in prior HCHS/SOL studies [21]. Data relating to medi-
cation use were self-reported at the time of the baseline examination
survey. Additionally, participants were instructed to bring all medica-
tions and supplements used during the last 4 weeks, which were subse-
quently reviewed and coded by the clinic staff.
2.4. Sociodemographic variables
Sociodemographic variables obtained included age, sex, education
level (less than high school, high school or equivalent, or beyond high
school), and income level. Acculturation was measured by four metrics:
Spanish language preference, years of residence in the US, nativity status
(foreign vs. US-born) and immigrant generation (first generation is
defined as foreign born with foreign born parents; 2nd generation in-
cludes individuals who are US born or those who are foreign born but
have at least one US-born parent). Insurance status and number of
healthcare visits in the past year were also obtained through surveys and
interviews.
2.5. Statistical analyses
Survey methods using sampling weights were used to obtain
weighted frequencies of descriptive variables and population estimates.
All weights were calibrated to the age, sex, and Hispanic/Latino back-
ground distributions from the 2000 US Census for the four study field
centers. Sociodemographic and clinical characteristics of the target
population by prevalent risk factor burden were presented with weighted
means  SE for continuous measures and frequencies (percentage) for
categorical measures. Statistical significance was assessed using survey
regression weighted least squares for continuous variables and Rao-Scott
Chi-Square test for categorical variables. Weighted logistic regression
models were used to assess the association of complete RF control for all
3 RFs by risk group. Multivariable models were adjusted for age, sex,
Hispanic/Latino background group, education, income, field center, and
insurance status. Odds ratios (ORs) were calculated to estimate the as-
sociations of risk factor burden and sociodemographic factors with risk
factor control. Age-sex adjusted interaction analyses were performed to
determine whether the association between CVD RF burden and RF
control was dependent on an individual’s education level and/or insur-
ance status. All analyses were performed using survey procedures in SAS
version 9.4 (SAS Institute, Cary, NC). A two-sided p-value of <0.05 was
considered statistically significant.
3. Results
Our analysis included 8521 participants with at least one self-
reported CVD RF or prevalent CVD. The sociodemographic characteris-
tics of HCHS/SOL target population by the number of CVD RFs are shown
in Table 1. The mean age of the target population was 49 (SE 0.3) years
and more than half were women (56%). Frequency of one, two, or three
self-reported CVD RFs was 57%, 26%, 8%, respectively, and 9% reported
established CVD. Individuals with a greater CVD RF burden were more
likely to be women and were older; however, those with prevalent CVD
were younger and more likely to be male. Hispanic/Latinos of Puerto
Rican and Cuban descent were more likely to have higher RF burden as
Table 2
Clinical characteristics by risk factor burden.
Risk Factor Burden p-value














































































































Antihypertensives: Angiotensin-converting enzyme inhibitors, Calcium Channel
Blocker, Thiazide/Thiazide-Like Diuretic, Beta Blockers and Angiotensin II Re-
ceptor Antagonists.
Antiplatelets: Platelet Aggregation Inhibitors such as Clopidogrel.
Lipid-Lowering drugs/Antihyperlipidemic including statins.
Antidiabetics including insulin.
All values are mean (.S.E.) or unweighted counts (weighted percentage), N (%)
unless otherwise specified.
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compared with those of Mexican descent. Individuals with higher CVD
RF burden were more likely to have a higher acculturation (as measured
by years in the US but no other acculturation metrics) and utilize
healthcare more frequently. Lower household income, less educational
attainment, and having health insurance were associated with a higher
number of CVD RFs.
Table 2 illustrates the clinical characteristics, stratified by the number
of CVD RFs or prevalent CVD. With higher number of CVD RFs, systolic
blood pressure, and glycemic control worsened despite greater medica-
tion use. Individuals with three CVD RFs had the highest mean values of
systolic blood pressure, BMI, and A1C. However, those with prevalent
CVD had lower cholesterol values and lower diastolic blood pressure
compared with CVD RF groups. Of note, only 48%, 43%, and 48% of
individuals with prevalent CVD were on aspirin, lipid-lowering therapy
and antihypertensives, respectively. A higher proportion of individuals
with three CVD RFs were on antihypertensives as compared to those with
prevalent CVD (67% vs. 48%) and on lipid-lowering therapies as
compared to those with prevalent CVD (58% vs. 43%).
The baseline characteristics stratified by the number of CVD RF
controlled are shown in Table 3. There was a lower proportion of in-
dividuals with all three CVD RFs controlled than with two CVD RFs
controlled. Those with higher number of CVD RF controlled tended to be
younger and female, and were more likely to prefer English to Spanish.
Table 4 shows the weighted, adjusted ORs of complete RF control for
all three RFs by RF burden and sociodemographic indicators. Compared
to individuals with one CVD RF, those with two RFs had 37% lower odds
of having their blood pressure, cholesterol, and glucose controlled;
whereas those with three RFs had 44% lower odds of having their risk
factors controlled. Furthermore, as compared with those who were
uninsured, participants with health insurance had 25% higher odds of
having CVD RFs controlled. The interaction analyses revealed that in-
surance status influences the relationship between RF burden and RF
control up to two CVD RFs (p < 0.01); with three CVD RFs and/or
prevalent CVD, insurance status had no effect (p > 0.05). Levels of
educational status did not modify the association between CVD RF
burden with CVD RF control on interaction analyses (p > 0.05).
Fig. 1 shows the proportions with RFs controlled according to self-
reported CVD RF burden combinations. Individuals with only one CVD
RF of hypertension, hypercholesterolemia, or diabetes had low rates of
the corresponding CVD RF control. For example, only 36% individuals
with just hypercholesterolemia had this CVD RF controlled, compared
with 58% of individuals who reported having all three CVD RFs. Those
with prevalent CVD were more likely to have higher proportions of in-
dividual RF control but only 40% had all CVD RFs controlled.
4. Discussion
4.1. Summary of findings
In this large sample of diverse Hispanic/Latino adults in the US, we
found significant variation in the prevalence of risk factor burden and
control across the spectrum of CVD. In general, individuals with a higher
self-reported burden of CVD RFs were less likely to have all 3 RFs
controlled. Those with prevalent CVD were more likely to have RFs
controlled. We also found significant heterogeneity in risk factor control
by sociodemographic factors including Hispanic/Latino background
groups, education, and acculturation.
4.2. Potential explanations
Our findings that a higher self-reported RF burden was associated
with lower RF control (despite more frequent healthcare utilization and
greater use of medications) is noteworthy and highlights an opportunity
to improve primary prevention efforts. Interestingly, individuals with
Table 3
Participant characteristics by risk factor control.
Total ¼ 8446 p-value
0 RF Controlled 1 RF Controlled 2 RF Controlled 3 RF Controlled
N (%) 176 (2%) 1451 (16%) 4068 (47%) 2751 (35%)
Age, mean (S.E.) 56 (1.4) 55 (0.5) 49 (0.4) 44 (0.5) <0.001
Female 108 (51%) 887 (55%) 2559 (55%) 1787 (58%) 0.376
Hispanic/Latino Background group <0.001
Dominican 13 (7%) 157 (11%) 376 (10%) 275 (12%)
Central American 20 (7%) 159 (8%) 378 (7%) 230 (5%)
Cuban 25 (20%) 285 (30%) 660 (24%) 318 (18%)
Mexican 60 (34%) 462 (29%) 1541 (33%) 1127 (38%)
Puerto Rican 43 (20%) 300 (18%) 743 (18%) 570 (19%)
South American 9 (5%) 55 (3%) 266 (5%) 160 (4%)
Others 6 (7%) 30 (2%) 97 (3%) 64 (3%)
Education <0.001
Less than high school 84 (48%) 661 (42%) 1581 (34%) 1148 (37%)
High school or Equivalent 36 (20%) 295 (22%) 948 (24%) 644 (28%)
Greater than HS 51 (32%) 467 (37%) 1458 (41%) 898 (35%)
Income 0.122
<$20,000 92 (55%) 708 (54%) 1849 (49%) 1300 (51%)
$20,001–40,000 49 (33%) 403 (31%) 1220 (31%) 800 (31%)
$40,001–75,00 15 (11%) 140 (11%) 481 (14%) 327 (12%)
>$75,000 2 (1%) 39 (4%) 168 (6%) 109 (6%)
Foreign-Born 161 (89%) 1313 (88%) 3580 (86%) 2293 (78%) <0.001
Years living in US, mean (S.E.) 26 (1.6) 24 (0.7) 23 (0.6) 23 (0.5) 0.101
Spanish Language Preference 152 (84%) 1257 (85%) 3449 (81%) 2198 (75%) <0.001
Immigrant Generation <0.001
1st 158 (86%) 1294 (87%) 3500 (84%) 2250 (76%)
2nd 17 (13%) 155 (13%) 558 (16%) 493 (23%)
Health Insurance (Yes) 98 (64%) 788 (57%) 2279 (57%) 1700 (63%) 0.004
# Doctor Visits in Past Year, mean (S.E) 3.1 (0.1) 2.9 (0.1) 2.8 (0.0) 2.9 (0.0) 0.110
Field center Bronx 56 (28%) 407 (28%) 1056 (29%) 769 (34%) <0.001
Chicago 32 (12%) 288 (10%) 961 (14%) 796 (16%)
Miami 48 (34%) 440 (39%) 1019 (32%) 507 (24%)
San Diego 40 (26%) 316 (23%) 1032 (25%) 679 (26%)
RF ¼ Risk factor.
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prevalent CVD (i.e. secondary prevention) were more likely to have CVD
risk factors controlled than those without prevalent disease. In recent
years, the American Heart Association and other groups have shifted to
focus on emphasizing primary prevention of CVD. For example, Life’s
Simple 7 emphasizes optimization of CV health with the presence of
seven metrics: not smoking, having a healthy diet, adequate physical
activity, healthy body weight, healthy blood pressure, and cholesterol,
and glucose [22]. However, almost no US adults meet all ideal CV health
metrics, with more pronounced disparities in CV health attainment
among Black and Hispanics/Latino individuals [23]. Controllingmultiple
cardiovascular risk factors is challenging and, as seen in our study, failure
to control one RF may be associated with worse control of other risk
factors [24]. With an increasing medication burden, it is possible that
participants in our study were less likely to be adherent to their medi-
cations and that the quality of the patient-provider interaction deterio-
rated. These patients may benefit from nurse or pharmacist-led intensive
interventions that improve medication adherence, patient-provider
interaction, clinical inertia and as a regular check on risk factor con-
trol. Furthermore, our work suggests that individuals with one CV risk
factor should be monitored and counseled extensively on preventing
additional risk factors.
Following a diagnosis of CVD, it is likely that individuals may be more
likely to adhere to medical therapy resulting in better RF control. In-
dividuals with CVD likely perceive their health risk at higher risk than
simply having one or multiple RFs and may be more motivated to engage
in appropriate secondary prevention strategies. Prior studies in pre-
dominantly non-Hispanic/Latino populations support these hypotheses
and note that RF control in those with established CVD may be improved
through higher medication adherence [25,26]. Similarly, hospitaliza-
tions for acute myocardial infarction, heart failure, or stroke may prompt
increased medication adherence since these provide “teachable mo-
ments” to motivate behavioral change.
4.3. In context to prior literature
Complementary to other studies, we also found significant differences
in CVD RF burden by Hispanic/Latino background group and four
acculturation metrics. Hispanics/Latinos with Puerto Rican and Cuban
background had a greater burden of CVD RF and worse RF control as
compared with those of Mexican descent. This association may be
mediated by other factors since Hispanic/Latino background group was
not independently associated with RF control in multivariable analysis.
This finding highlights the importance of disaggregating Hispanics/
Latinos into subpopulations since health risks, behaviors, and outcomes
differ substantially and primary prevention efforts need to be tailored
accordingly [27,28]. Longer length of stay in the US was associated with
a higher CVD RF burden. Higher acculturation has generally been linked
to greater risk of CVD [29,30], although results are mixed and vary
depending on the acculturation metric studied [31,32]. We found that
Spanish language preference and foreign-born status – both measure of
lower acculturation – predicted poorer RF control. These findings un-
derscore the importance of disaggregating Hispanic/Latino CVD data by
background and varied acculturation metrics.
Inadequate RF control among Hispanics/Latinos with a high burden
of CVD risk factors may also be attributable to health care system factors
such as access to care or provider treatment inertia. This disconnect may
be a contributing factor to provider treatment or a patient’s lack of
adherence to medical therapy. We found less than half of the Hispanic/
Latino population with prevalent CVD were on aspirin, antihypertensives
and lipid-lowering therapy. Hispanic/Latino patients may be particularly
vulnerable to inadequate shared decision making due to language bar-
riers and other cultural differences. In fact, we found that Spanish lan-
guage preference was associated with lower RF control and more
frequent doctor’s visits (a metric for interactions with the healthcare
system) along having health insurance resulted in improved CVD RF
control.
Interestingly, having a sole CVD RF was associated with low levels of
control of that specific CVD RF. It is possible that individuals with more
comorbidities were more adherent to lifestyle and pharmacotherapy that
led to improved individual CVD RF control. Other studies have also
documented this counter-intuitive finding that increasing number of
medications is positively associated with adherence and improved CVD
RF control [25,33,34]. Sicker patients may be more attune to their health
and be more likely to regularly comply with their drug therapies. We
extend this finding to a diverse cohort of Hispanic/Latino adults. How-
ever, individuals with three self-reported CVD RF represented a group
that was particularly vulnerable to poor CVD RF control. This highlights a
population that may require additional attention and resources to ensure
initiation and adherence to preventive therapies.
Table 4
Association of risk factor burden with risk-factor controla.
Multivariable-Adjusted Models
OR (95% CI) P value
Overall Pairwise
Age (per year) 0.97 (0.96,
0.98)
<0.001 –







































Years living in US 1.00 (0.99,
1.01)
0.892 –




Foreign Born US born Referent 0.530 –
Not US born 0.75 (0.30,
1.85)
–








CV Risk Factor Burden 1 RF referent <0.001 –
2 RF 0.63 (0.50,
0.78)
<0.001








# Doctor Visits in Past Year 1.17 (1.07,
1.28)
0.001 –







San Diego 0.81 (0.49,
1.33)
–
a Defined as having all 3 CVD RFs controlled (hypertension, diabetes, and
hypercholesterolemia).
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4.4. Limitations
Our study should be interpreted in light of several limitations. First,
our study design was cross-sectional and limits our ability to infer cau-
sality or longitudinal associations of RF burden and control over time.
HCHS/SOL was designed to be the largest epidemiologic study of
community-dwelling US Hispanics/Latinos but was not designed to be
nationally representative; but it is the most generalizable cohort of US
Hispanics/Latinos to date. We focused only on self-reported CVD RFs and
it is likely that a proportion of participants are unaware of their risk
factors, as reported in other HCHS/SOL publications [20,21,35]. We
focused on only three CVD RFs and their control (blood pressure,
cholesterol, and glucose) and recognize that other lifestyle factors such as
physical activity and a healthy diet are important contributors to optimal
CVD health. Prior work in HCHS/SOL documented an overall low
achievement of optimal cardiovascular health including physical activity
in Hispanic/Latino populations, with significant heterogeneity by ethnic
background and sociocultural factors [36]. Furthermore, CVD RF iden-
tification and subsequent management may differ across the geographic
regions that HCHS/SOL was sampled from which could affect partici-
pant’s awareness and control of self-reported CVD RFs.
4.5. Clinical implications
Because Hispanics/Latinos are the largest minority population in the
US, understanding CVD RF control across the CVD risk spectrum is
essential for the development of targeted interventions. Our work sug-
gests that patients with multiple CV risk factors may be particularly
vulnerable to poor risk factor control and should be the focus of intensive
clinical interventions. Future studies should further disentangle the role
of risk factor awareness, health care system factors (access to care, pro-
vider inertia) and medication non-adherence in CVD RF control.
5. Conclusion
In a large sample of diverse Hispanic/Latino adults, we found that
individuals with 3 self-identified major CVD RFs – but not yet overt CVD
– appear to represent a group especially prone to poor overall CVD RF
control. Those with prevalent CVD had improved CVD RF control as
compared to those with less CVD RF burden. These findings identify and
underscore a potential missed opportunity for CVD prevention focused
interventions in a particularly vulnerable subset of the population at
large.
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